<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">26114161</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>03</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">2374-2445</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>1</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2015</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>JAMA oncology</Title>
<ISOAbbreviation>JAMA Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>369-74</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Blinding patients to treatment regimen is an important component of high-quality randomized clinical trials, although concern exists about how receipt of a placebo will affect participants' views, particularly among patients with cancer.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether unblinding of random assignment to placebo vs experimental agent in a large adjuvant breast cancer chemotherapy randomized clinical trial was associated with perception of greater chance of cancer recurrence and lower confidence in the decision to participate in the trial in participants who were randomized to placebo compared with those randomized to experimental therapy.</AbstractText>
<AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Serial telephone-based prospective survey substudy of all Eastern Cooperative Oncology Group Protocol 5103 (ECOG5103) participants enrolling between January 5 and June 8, 2010. In ECOG5103, patients were randomized to receive standard adjuvant chemotherapy for breast cancer with either placebo or bevacizumab for either approximately 6 or approximately 12 months. Treatment assignment was unblinded by 24 weeks, and then patients were surveyed.</AbstractText>
<AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Trial participants' self-reported perceived risk of recurrence and confidence in study participation.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 571 patients in this substudy who started protocol therapy, 550 were still in the study at unblinding and 492 (89%) responded to the unblinding survey. At unblinding, 336 of 477 (70%) believed that they had at most a small risk of breast cancer recurrence, and 342 of 480 (71%) reported perceiving at most a small risk of serious problem with therapy; most reported feeling very informed (421 of 483 [87%]) and having high levels of confidence in their study participation (420 of 483 [87%]). The 102 participants who learned that they had been randomized to placebo did not have greater perception of chance of recurrence (P = .48) or fear of recurrence (P = .69), feel less informed (P = .86), or have lower confidence in trial participation (P = .31) compared with the 390 participants who had been randomized to experimental therapy. Patients who learned that they had been randomized to bevacizumab perceived higher risk of having a serious problem caused by treatment (P = .01).</AbstractText>
<AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In a placebo-controlled, double-blind randomized clinical trial of chemotherapy for breast cancer, unblinding to randomization allocation did not significantly affect most participants' views except for chance of a serious problem from experimental treatment, regardless of receipt of placebo or experimental anticancer therapy along with standard chemotherapy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Partridge</LastName>
<ForeName>Ann H</ForeName>
<Initials>AH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sepucha</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Neill</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>Kathy D</ForeName>
<Initials>KD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Motley</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Swaby</LastName>
<ForeName>Ramona F</ForeName>
<Initials>RF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schneider</LastName>
<ForeName>Bryan P</ForeName>
<Initials>BP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dang</LastName>
<ForeName>Chau T</ForeName>
<Initials>CT</Initials>
<Suffix>Jr</Suffix>
</Author>
<Author ValidYN="Y">
<LastName>Northfelt</LastName>
<ForeName>Donald W</ForeName>
<Initials>DW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sledge</LastName>
<ForeName>George W</ForeName>
<Initials>GW</Initials>
<Suffix>Jr</Suffix>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>U10 CA032291</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA027525</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA180795</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA66636</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA021115</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA77651</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA180820</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA27525</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA049883</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA180795</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA066636</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UG1 CA189828</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA077651</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA180794</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA180820</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA25224</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA023318</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA180794</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA180816</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA49883</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA21115</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA025224</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA23318</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA180816</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA33229</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>JAMA Oncol</MedlineTA>
<NlmUniqueID>101652861</NlmUniqueID>
<ISSNLinking>2374-2437</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068258">Bevacizumab</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017024">Chemotherapy, Adjuvant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007722">Health Knowledge, Attitudes, Practice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007258">Informed Consent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010465">Perception</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010919">Placebos</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012107">Research Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035842">Research Subjects</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>3</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26114161</ArticleId>
<ArticleId IdType="doi">10.1001/jamaoncol.2015.0246</ArticleId>
<ArticleId IdType="pmc">PMC4477538</ArticleId>
<ArticleId IdType="mid">NIHMS696474</ArticleId>
</ArticleIdList>
<?nihms ?>
<ReferenceList>
<Reference>
<Citation>Health Technol Assess. 2005 Mar;9(8):1-192, iii-iv</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15763039</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2003 Jan 1;95(1):19-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12509397</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drugs. 2007;67(12):1793-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17683175</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Med Decis Making. 2010 Sep-Oct;30(5 Suppl):20S-34S</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20393104</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer Res Treat. 2010 Dec;124(3):835-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20446031</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Evid Based Healthc. 2011 Sep;9(3):215-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21884450</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Health Serv Res. 2005 Apr 22;5(1):30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15847683</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pers Soc Psychol. 2007 Oct;93(4):515-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17892329</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 2002 Dec 7;325(7376):1329</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12468480</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Oncol. 2012;2012:417673</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23008712</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1998 Jan 1;82(1):208-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9428499</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Urol. 2003 Nov;170(5):1931-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14532810</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2008 Mar 10;26(8):1371-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18227527</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Contemp Clin Trials. 2007 Nov;28(6):684-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17434812</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2012 Feb;23(2):331-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21821545</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Psychooncology. 2007 Oct;16(10):895-903</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17245695</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2009 Feb 20;27(6):838-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19164202</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Breast Cancer. 2005 Jun;6(2):99</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16001986</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 2002 Jul 17;288(3):363-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12117402</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1183-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18217977</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncol Nurs Forum. 2010 Nov;37(6):E387-99</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21059572</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2003 Mar 19;95(6):491-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12644548</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Qual Health Res. 2012 Aug;22(8):1138-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22673094</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Health Psychol. 2007 Mar;26(2):146-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17385965</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Kennedy Inst Ethics J. 2003 Dec;13(4):329-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15049297</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer Res Treat. 2009 May;115(1):123-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18543100</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2002 Dec 18;94(24):1847-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12488478</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1997 Nov 15;80(10):1936-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9366296</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2013 Dec 5;369(23):2179-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24304050</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>IRB. 1983 May-Jun;5(3):7-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11649518</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hastings Cent Rep. 2003 May-Jun;33(3):19-28</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12854452</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>IRB. 1998 Jul-Aug;20(4):1-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11657084</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Health Expect. 2014 Feb;17(1):4-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22070416</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>